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1  Introduction
embryonic stem cell (eSC)-based novel test systems are amongst 
the most dynamic areas of in vitro toxicology and biomedicine, 
and their development is funded e.g. by a large scale eU project 
(eSNAtS  http://www.esnats.eu/). they may become future 
alternatives to animal testing and a key element of modern risk 
assessment approaches (Pellizer et al., 2005). At the start of such 
a	paradigm	shift	in	toxicology	it	is	essential	to	define	the	new	test	
systems and their performance to the maximum possible degree. 
Therefore	this	review	undertakes	a	first	attempt	to	define	markers	
for meSC and derived cell types as a starting point for an intense 
scientific	discussion	and	further	improvements	in	this	area.
* a report of t4 – the transatlantic think tank for toxicology, reviewed by T. Hartung and A. Goldberg (Baltimore, MD, USA)
 This manuscript has been reviewed by the National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, and 
approved for publication. Approval does not signify that the contents reflect the views of the Agency, nor does mention of trade names or commercial 
products constitute endorsement or recommendation for use.
Summary
Developmental neurotoxicity (DNT) is a serious concern for environmental chemicals, as well as for food 
and drug constituents. Animal-based DNT models have relatively low sensitivity, and they are burdened by 
high work-load, cost and animal ethics. Murine embryonic stem cells (mESC) recapitulate several critical 
processes involved in the development of the nervous system if they are induced to differentiate into neural 
cells. They therefore represent an alternative toxicological model to predict human hazard. In this review, 
we discuss how mESC can be used for DNT assays. We have compiled a list of mRNA markers that define 
undifferentiated mESC (n = 42), neural stem cells (n = 73), astrocytes (n = 25) and the pattern of different 
neuronal and non-neuronal cell types generated (n = 57). We propose that transcriptional profiling can 
be used as a sensitive endpoint in toxicity assays to distinguish neural differentiation states during normal 
and disturbed development. Importantly, we believe that it can be scaled up to relatively high throughput 
whilst still providing rich information on disturbances affecting small cell subpopulations. Moreover, this 
approach can provide insight into underlying mechanisms and pathways of toxicity. We broadly discuss the 
methodological basis of marker lists and DNT assay design. The discussion is put in the context of a new 
generation of alternative assays (embryonic stem cell based DNT testing = ESDNT V2.0), that may later 
include human induced pluripotent stem cells, and that are not designed for 1:1 replacement of animal 
experiments, but are rather intended to improve human risk assessment by using independent scientific 
principles.
Keywords: stem cell, development, neurotoxicity, gene ontology, astrocyte, systems biology
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of methylmercury intoxication, autopsy studies revealed that 
this compound targeted the fetal neural system (e.g. eto et al., 
1992),	and	thereby,	Minamata	disease	contributed	significantly	
to	 the	 identification	of	developmental	neurotoxicity	 (DNT)	as	
an important endpoint in toxicology. 
At the same time, the problem of developmental ecotoxicol-
ogy (e.g. reduced reproductive success of birds due to pesticides 
in their food chain) was introduced by Rachel Carson in her book 
“silent spring”. the above mentioned examples provide insights 
into	the	specific	problems	of	DT.	Another	example	for	specific	
DNT	issues	is	thalidomide	that	has	a	defined	“window	of	sensi-
tivity”. It did not cause problems when taken by pregnant women 
earlier than about 20 days after conception or later than about 35 
days after conception. However, within this window it caused 
different effects, such as facial paralysis, when taken rather early, 
malformations of arms and legs in the middle and e.g. deformi-
ties of the intestine when only taken late during the window of 
sensitivity. Notably, although thalidomide acted as a sedative in 
rats and mice (just as in humans), it had no teratogenic effects in 
these rodent species most frequently used for toxicity testing. 
In Minamata, Chisso Corporation was found responsible for 
having caused the disease by introducing mercury waste into the 
Minamata	bay.	However,	it	was	much	more	difficult	in	the	case	
of the victims of the congenital disease (who had never eaten 
contaminated	fish,	 but	 had	been	 exposed	 in	utero)	 to	prove	 a	
causal relationship between their disease and the methylmer-
cury contamination. the situation was similar with other envi-
ronmental contaminants, where a cause-effect relationship was 
disputed until R. Carson’s book became one of the key triggers 
for a wave of public concern that resulted in the ban of dichlor-
diphenyltrichlorethane (DDt). these examples illustrate the 
specific	problems	of	the	discipline	of	developmental	toxicology,	
i.e.	the	difficulty	to	provide	evidence	for	cause-effect	relation-
ships, and to identify suitable test systems. this fundamental 
weakness is also evident from less dramatic and more prevalent 
human poisonings that have reached the pandemic scale. the 
most prominent example of such an omnipresent contaminant is 
lead. It causes human developmental neurotoxicity, associated 
with a reduction of intelligence estimated to have resulted in an 
economic cost of > 100 billion $/year for each birth cohort born 
between 1960 and 1990 (Grandjean and landrigan, 2006). the 
average lead blood levels in children fell by 90% after the even-
tual ban of lead additives to gasoline (Grandjean and landrigan, 
2006). However, those exposed earlier may keep suffering from 
lead neurotoxicity due to its long biological half-life in addition 
to the DNt effects (Cory-Slechta, 1990). In the case of the de-
velopmental toxicity of lead, the overwhelming epidemiological 
evidence	finally	helped	to	convince	regulators	to	reduce	accept-
able thresholds, and the availability of trustworthy human ref-
erence data helped to optimise a suitable experimental system 
to improve the toxicity evaluation. there are still many other 
wide-spread contaminants with effects below the threshold of a 
pandemic, but with the potential to affect a large population.
For most of these hazardous compounds evidence from hu-
man epidemiology is not available. therefore, standardised 
test systems, mainly rodent-based bioassays, are used to de-
rive points of departure (POD) for human health risk assess-
Murine embryonic stem cells (meSC) are pluripotent cells 
able to differentiate into all cell types in the mouse, including 
functional germ cells. Under appropriate conditions, meSC can 
be kept as in vitro	cultures	with	an	indefinite	capacity	for	self-
renewal (evans and Kaufman, 1981; Martin, 1981). the deriva-
tion, use and properties of murine and human embryonic stem 
cells (eSC) have been reviewed earlier (leist et al., 2008a), 
also with the perspective of generating induced pluripotent stem 
cells (iPSC) by reprogramming of somatic cells from various 
species, including humans (Baker, 2010; Nagy and Nagy, 2010; 
lee and Studer, 2010). Pluripotent cells are suitable for molecu-
lar biological manipulations, such as homologous recombina-
tions with exogenous DNA to alter sequences of their genome. 
these properties have been used successfully for the generation 
of	knock-out	and	knock-in	mice	from	modified	mESC	(Capec-
chi, Martin and Smithies, Nobel Prize 2007). Such mice stand 
as in vivo proof that every stage and every cell of the nervous 
system can develop from meSC under appropriate conditions, 
and that the produced cells display different phenotypes accord-
ing to the genotype of the meSC used initially for generation 
of the mice. It has also been demonstrated, that meSC can dif-
ferentiate in vitro to different neuronal or glial subtypes (Wobus 
and Boheler, 2005). In theory, this offers the possibility to study 
all steps – in detail, in real time and at the resolution of indi-
vidual cells –  that lead from the multipotent meSC to the for-
mation of neuroectoderm tissue, and further to the generation of 
neural stem cells (NSC), neuroblasts and various intermediate 
and mature types of neural cells (Bain et al., 1995; Fraichard et 
al., 1995; Strübing et al., 1995; Ying and Smith, 2003; Conti et 
al., 2005). the in vitro differentiation of meSC or human eSC 
(heSC), as well as of murine or human iPSC or neural precur-
sor	cells	(NPC)	to	neurons	or	other	defined	cell	types	is	of	high	
interest to the understanding of developmental biology, but also 
its disturbances. thus, such test systems appear useful for the 
examination	of	teratogenicity	and	the	wide	field	of	reproductive	
toxicity (Rt). Moreover, introduction of neural endpoints rel-
evant for developmental neurotoxicity (DNt) at different stages 
of development and development of more predictive and more 
sensitive	model	systems	may	significantly	improve	this	testing	
strategy (Breier et al., 2009; Moors et al., 2009; Coecke et al., 
2007; lein et al., 2007). 
2  Towards new test systems for developmental 
neurotoxicity
2.1  Lessons from the history of developmental 
neurotoxicity (DNT) testing
the area of developmental toxicology (Dt) came into public 
focus 50 years ago. At that time, the drug thalidomide caused 
severe birth defects, while the metal-organic contaminant meth-
ylmercury caused Minamata disease (Harada, 1995). the latter 
also includes a congenital form, which is triggered by exposure 
of the unborn fetus to the toxicant. It has been shown that the 
mercury	concentration	 in	umbilical	cord	blood	can	be	signifi-
cantly higher than in the maternal blood (Sakamoto et al., 2004). 
Decades later, but still in consequence of this miniepidemic 
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substances should all be evaluated for their reproductive toxicity, 
experiments involving millions of animals would be performed 
to satisfy the legal requirements (Hartung and Rovida, 2009). 
However, these tests of individual chemicals constitute only the 
tip	of	the	iceberg.	Practically,	and	scientifically,	we	should	also	
consider mixtures of compounds that humans and the environ-
ment are exposed to. Already a dozen compounds can form thou-
sands of different mixtures, which would be impossible to test by 
classical toxicological approaches based on animal experiments. 
even though some of the most relevant chemicals will be tested 
for their effects on reproduction, these tests will most likely leave 
open the safety questions concerning low dose effects on DNt. 
As indicated above, testing for Dt in the low-dose range and 
basing	legal	decisions	on	these	data	has	proven	very	difficult,	if	
not impossible, in most cases. this is even more an issue for the 
subarea of DNt. Within the ReACH testing requirements, DNt 
is	only	addressed	in	exceptional	cases	triggered	by	positive	find-
ings from other studies. Dedicated studies are otherwise not re-
quired. thus, the concern remains that subtle, and predominantly 
functional, DNt effects triggered by chemicals might remain 
undiscovered. A comprehensive safety assessment will therefore 
require alternative approaches. technical (limited test capaci-
ties),	ethical	(reduction	of	animal	testing)	and	scientific	reasons	
call for new strategies in toxicology testing (leist et al., 2008b; 
Hartung, 2009a; Stingl et al., 2009; Bottini et al., 2007). One 
such strategy was suggested by the National Research Council 
(NRC, 2007). this milestone publication has been described in 
many reviews (Collins et al., 2008; leist et al., 2008c; Hartung 
and leist, 2008; Hartung, 2009b), and the strategy is now often 
summarised under the heading “tox21c” (toxicology for the 21st 
century).	Two	changes	are	particularly	important:	first,	novel	test	
systems would be based on cell cultures (human, where possible) 
and	simple	model	organisms	(e.g.	worms	and	flies)	instead	of	ro-
dents and other higher vertebrates; second, the essential primary 
endpoints should cover disturbances of cellular (e.g. signalling, 
metabolic, homeostatic, proliferation, differentiation) pathways, 
and the overall resulting toxicological effect on humans would 
be predicted by systems biology-based approaches from these 
mechanistic data. the vision is that the new test systems would 
allow a much higher throughput of compounds and would work 
better in the low-dose range relevant for human exposure. the 
use of a systems-based approach (e.g. omics data, quantitative 
models linking cellular processes to adverse effects) is expected 
to be more predictive of human toxicity (see above issue of ro-
dent testing of thalidomide). Added value may come from the 
possibility to use and to compare cells of different species, in-
cluding humans.
For this vision to become reality, the new methods must be 
trusted and accepted globally (Bottini and Hartung, 2009; Bottini 
et	al.,	2007).	For	instance,	technical/scientific	barriers	are	linked	
to the problem of validation (Hartung, 2007), as detailed for 
the areas of food safety and cosmetics safety (Hartung, 2008b; 
Hartung and Koëter, 2008; Vogel, 2009). New technologies and 
ideas can be imported and developed with specialists of other 
disciplines (e.g. Mitterhauser and toegel, 2008; Schrattenholz 
and Klemm, 2007), and teaching of alternative approaches may 
be achieved in different ways (Jukes, 2008; Jukes, 2009; leist, 
ment in regulatory toxicology. In the 1960s, it became evident 
that developmental exposure to chemicals and drugs can alter 
behavioural function in young and adult animals (e.g. Werboff 
and Dembicki, 1962). As an indirect measure of neurotoxicity, 
behavioural readouts have been used and validated since the 
1960s. these behavioural alterations are considered as an ob-
servable expression of effects on nervous system function (Re-
iter, 1978). therefore, guidelines and test batteries have been 
developed (Moser and MacPhail, 1990, 1992) and validated 
for use in behavioural toxicology. In the 1980s, the U.S. en-
vironmental	Protection	Agency	(U.S.	EPA)	developed	the	first	
DNt guidelines and initiated the standardisation of this testing 
strategy by the Organisation of economic Co-operation and De-
velopment (OeCD). the development of the pertinent OeCD 
test	guideline	426,	which	was	finally	accepted	in	2007	(Makris	
et	al.,	2009),	was	guided	by	two	ideas:	first,	the	methods	need	
to yield reproducible results within and across laboratories, and 
second, they must be sensitive to the effects of a range of neu-
rotoxic agents (Middaugh et al., 2003). A recent review (Makris 
et al., 2009) revealed that just over 100 compounds have been 
tested in studies using the OeCD 426 draft guideline. Most of 
these compounds were pesticides (66%) and only 8 industrial 
chemicals	were	included.	Another	review	identified	about	174	
compounds for which neurobehavioural risk assessment had 
been performed, in many cases also on the offspring of the ex-
posed animals (F1 generation). Only 1% of these compounds 
were industrial chemicals (Middaugh et al., 2003). the avail-
able data for this relatively new area of toxicology of industrial 
chemicals is therefore rather limited. Some of the studies indi-
cate that compounds exist for which DNt testing is the most 
sensitive of all toxicity endpoints in a broad safety evaluation 
battery. therefore inclusion of DNt testing in compound safety 
evaluation programmes such as ReACH is likely to add impor-
tant information for regulatory decisions (Makris et al., 2009; 
Middaugh et al., 2003). At present the available data is insuf-
ficient	to	predict	how	representative	these	findings	are.	
In summary, the historical development of DNt testing strate-
gies was strongly based on the statistical concepts of reliability 
and sensitivity, and biological modes of action played a relatively 
minor role. In addition to the relatively low numbers of animal 
studies, few human reference data are available. thus, the predic-
tive value of traditional DNt testing for human health is hard to 
estimate. establishment of alternative and additional approaches 
remains	a	huge	scientific	challenge	requiring	new	strategies.
2.2  The road to a mechanism-based 
developmental toxicology
the number of chemicals with potential for environmental ex-
posure is large. the new european law entitled ReACH trig-
gered an administrative procedure aiming at registration, evalu-
ation and authorisation of all chemicals produced in the eU at 
> 1 t/year and not tested under the chemical safety law of 1982. 
It is expected that at least 30,000 chemicals will be registered, 
amongst these several thousand that are produced or used at > 100 
t/year (Rovida and Hartung, 2009). A considerable percentage of 
these chemicals is found in the environment or at work places, 
where human exposure could potentially trigger Dt. As these 
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ing, standardisation of protocols and exploratory activities, and 
a large variety of different approaches should be promoted and 
explored	for	a	sufficiently	long	time	before	a	rational	selection	
process can be initiated with the goal of identifying a smaller set 
of assays that may be used for regulatory decisions. therefore 
only some general considerations are highlighted here:
3.1.1  Species
For human predictivity, heSC may appear more promising than 
rodent systems. However, for comparison with already exist-
ing murine and rat in vivo databases, meSC may be more suit-
able. In general, meSC presently represent a system with higher 
throughput and robustness: neurons are generated much faster 
and with higher yield than in the human system. As many more 
laboratories have worked with meSC compared to heSC, there 
is more experience in using the murine cultures. they are easier 
to handle, and the tools to genetically modify these cells are 
more advanced, while heSC show considerable variability in 
vivo and in vitro (Parsons et al., 2009; Wu et al., 2007; Osafune 
et al., 2008; Abeyta et al., 2004). It is also evident that heSC 
2006; Hartung et al., 2009). However, much research in the 3R 
field	 addresses	 technical	 problems	 within	 already	 established	
concepts (e.g. Rothen-Rutishauser, 2008; Heindl, 2008; Wan-
ner, 2008; li, 2008a,b; Hagelschuer et al., 2009; Bahramsoltani 
et al., 2009; Manzer et al., 2009; Hartung and Hoffmann, 2009; 
Sauer et al., 2009). the next generation of methods (see chapter 
below on eSDNt V2.0) should set its own standards instead of 
aiming at a 1:1 substitution of existing animal protocols with 
their own set of problems (Hartung, 2008a; Pelkonen et al., 
2009; Vedani et al., 2009; Sauer, 2009).
3  Markers for DNT testing
3.1  Challenges for an in vitro DNT test system
A number of questions arise when one considers develop-
ing meSC, iPSC or heSC as potential test systems for DNt. 
these involve species, source, genotype, developmental status, 
throughput and endpoints of the model system. At the present 
stage, all different options and their combinations require test-
Tab. 1: Marker genes for mESC
name accession full name comment ref 
 number 
Bat1a NM_019693 HLA-B-assoc. transcript 1A  [1]
Cd9 NM_007657 Tspan29 cell migration and adhesion [2]
Cxxc1 NM_028868 Cgbp, Cxxc finger 1 (PHD domain) Cgbp knock-out cells are viable but unable  
   to differentiate upon removal of LIF [3]
Myc NM_010849 C-myc, myelocytomatosis oncog.  [4]
Dppa2 NM_028615 dev. plurip.-assoc. 2  expressed in human pluripotent stem and  [5], [6] 
   germ cells  
Dppa3 NM_139218 Stella, dev. plurip. Assoc. 3  [6]
Dppa4 NM_028610a) dev. plurip. assoc. 4    inner cell mass [6], [5]
Dppa5a NM_025274 Esg1, dev. plurip. assoc. 5     [6], [23]
2410004A20-RIK NM_025890 Ecat1, ES cell assoc. transcript 1  also called Oeep 48 [7]
Eras NM_181548 Ecat5, ES cell-expressed Ras involved in the control of ES cell proliferation [8], [9], [10]
Esrrb NM_011934b) estrogen receptor, beta activates Oct4 transcript., sustains self- [11], [12] 
   renewal and plurip. 
Fbxo15 NM_015798 ecat3, F-box only protein 15 target of Oct4/Sox2 [8], [13], [14]
Fgf4 NM_010202 fibroblast growth factor 4 target of Oct4/Sox2,  activates Erk [15], [14]
Gab1 NM_021356 GRB2-assoc. binding protein 1  expressed in blastocyst [16], [17]
Gjb3 NM_008126c) Cx31, Connexin 31 gap junction protein, specific for mESC [18]
Gnl3 NM_178846d) Nucleostemin low in EB, but also expressed in NPC [19], [20]
Khdc1a NM_183322 KH domain containing 1A member of the Khdc1/Dppa5/Ecat1/Oeep family [7], [21]
Khdc1b XR_031927e) Khdc1c, KH domain cont. 1C member of the Khdc1/Dppa5/Ecat1/Oeep family [21]
Klf4 NM_010637 Kruppel-like factor 4 inhibits cell differentiation, target of Oct4/Nanog [22], [23]
Klf5 NM_009769 Kruppel-like factor 5 related to Klf4 [24]
Lefty2 NM_177099 left-right determination factor 2    antagonistic Tgfbeta ligand, sometimes called Leftb [25]
Lefty1 NM_010094 Left-right det. factor 1 target of Klf4/Oct4/Sox2 [26], [27]
Lin28 NM_145833 ln-28 homolog  reprogramming factor, RNA-binding protein [28], [29]
Msh2 NM_008628 mutS homolog 2 DNA repair protein, downregulated during diff. [30]
Msh6 NM_010830 mutS homolog 6 DNA repair protein, downregulated during diff. [30], [31]
Nanog NM_028016f) Nanog homeobox  [8], [32]
Phc1 NM_007905g) polyhomeotic-like 1  regulation of Hox genes via Polycomb [33]
Phf17 NM_172303h, i, j) Phd finger protein 17  [34] 
Pou5f1 NM_013633 Oct4, POU domain, class 5,  transcription factor regulating plurip. [14], [32] 
  transcription factor 1  
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behave differently from meSC concerning the pathways that 
control stemness. It has been suggested that they correspond to 
epiblast stem cells rather than to inner cell mass-derived cells, 
as do meSC, and they may not be able to form chimeras and an 
organism (li and Ding, 2009). Continuing basic research on ro-
bust and more rapid heSC protocols is still needed to eventually 
provide a model system that avoids the species differences and 
the necessity for an interspecies extrapolation.
3.1.2  Type of cells used as starting material
Different cell types have been used to study aspects of DNt. 
eSC are derived from the inner cell mass of blastocysts (Mar-
tin, 1981; evans and Kaufman, 1981; reviewed in leist et al., 
2008a), and, using eSC-based models, all developmental steps 
are accessible for examination (Winkler et al., 2009). the down-
side of this approach is that the cells need to be directed through 
all differentiation steps, preferably in a synchronised way, even 
under circumstances when only information on the last step is 
of interest. to avoid this problem, various other cell types have 
been used to study particular stages of DNt. For instance pri-
mary neurons or certain neuroblastoma, phaeochromocytoma or 
teratoma cells can differentiate to a partially neuronal pheno-
type (e.g. axonal elongation and maturation), and this forms the 
basis for many test systems, which are of more limited scope but 
often of high reproducibility and throughput (Radio and Mundy, 
2008; Radio et al., 2008, 2009; Hogberg et al., 2009, 2010). An 
intermediate solution would be the use of neural stem cells or 
neuroblast-like cells, which may be developed from eSC and 
that do not necessitate the initial differentiation steps required 
for eSC but still have the potential to develop into a number 
of different, morphologically and functionally mature neuronal 
and glial cell types (Buzanska et al., 2009; Breier et al., 2008; 
Wang et al., 2007). the advantages and disadvantages of such 
systems illustrate an important issue of DNt testing. the down-
side is that such NSC-based systems cannot model the initial 
phase	of	neuroectoderm	specification	and	formation.	Thus,	the	
effect of compounds on this developmental period, associated 
with an important coordinated wave of gene transcription, can-
not be tested. the upside of the use of NSC is that other phases, 
e.g. the step from NSC or neuroblasts, can be examined with 
name accession full name comment ref 
 number 
Rest NM_011263 RE1-silencing transcription factor  maintains self-renewal and plurip.,  [35-39] 
   (also NSC), discussed 
Sox2 NM_011443 SRY-box containing gene 2  transcription factor regulating plurip., (also NSC) [14], [32]
Stat3 NM_213660k, l) signal transducer and activator   involved in LIF signaling [40], [23] 
  of transcription 3  
Stip1 NM_016737 stress-ind. phosphoprot. role in plurip. signaling  [41]
Tcfcp2l1 NM_023755 transcription factor CP2-like 1  [2], [23]
Tdgf1 NM_011562 Cripto, teratocarcinoma-derived target of nanog, Oct4, SMAD [8], [42] 
  growth factor 1  
Tdh NM_021480 L-threonine dehydrogenase  [43]
Tead4 NM_011567 TEA domain family member 4,  expressed from 2 cell stage on to blastocyst  [44] 
  TEF-1-related factor 1  
Tert NM_009354 telomerase (RT) reverse transcriptase   [45]
Tex19.1 NM_028602 Nuclear protein also germ line [46]
Timp1 NM_011593m) tissue inhibitor of metallo-  [2], [47] 
  proteinase 1  
Utf1 NM_009482 undifferentiated embryonic cell  target of Oct4/Sox2 [8], [14], 
  transcription factor 1  [48-50]
Zfp42 NM_009556 Rex1, zinc finger protein 42  [8]
Zic3 NM_009575 zinc finger protein of the required for maintenance of plurip. in ES cells [51], [52] 
  cerebellum 3 and neural crest development 
Additional accession numbers:  
a) NM_001018002, b) NM_001159500, c) NM_001160012, d) NM_153547, e) NM_001033904, f) NM_001080945, g) NM_001042623,  
h) NM_001130184, i) NM_001130185, j) NM_001130186, k) NM_213659, l) NM_213660, m) NM_001044384
1. Sharov et al., 2003; 2: Abranches et al., 2009; 3. Carlone et al., 2005; 4. Lewitzky and Yamanaka, 2007;  
5. Maldonado-Saldivia et al., 2007; 6. Bortvin et al., 2003; 7. Imamura et al., 2006; 8. Mitsui et al., 2003;  
9. Takahashi et al., 2003; 10. Sorrentino et al., 2007; 11. Zhang et al., 2008; 12. Feng et al., 2009;  
13. Tokuzawa et al., 2003; 14. Okumura-Nakanishi et al., 2005; 15. Kunath et al., 2007; 16. Schaeper et al., 2007;  
17. Xie et al., 2005; 18. Worsdorfer et al., 2008; 19. Tsai and McKay, 2002; 20. Beekman et al., 2006; 21. Pierre et al., 2007;  
22. Li et al., 2005; 23. Wei et al., 2005; 24. Ema et al., 2008; 25. Hamada et al., 2001; 26. Farthing et al., 2008;  
27. Nakatake et al., 2006; 28. Hagan et al., 2009; 29. Hanna et al., 2009; 30. Roos et al., 2007; 31. Mason et al., 2009;  
32. Chambers and Tomlinson, 2009; 33. Isono et al., 2005; 34. Tzouanacou et al., 2003; 35. Singh et al., 2008;  
36. Canzonetta et al., 2008; 37. Johnson et al., 2008; 38. Buckley et al., 2009; 39. Jørgensen et al., 2009;  
40. Kues et al., 2005; 41. Longshaw et al., 2009; 42. Liu et al., 2005; 43. Wang et al., 2009; 44. Nishioka et al., 2009;  
45. Armstrong et al., 2005; 46. Kuntz et al., 2008; 47. Singla and McDonald, 2007; 48. van den Boom et al., 2007;  
49. Nishimoto et al., 2005; 50. Okuda et al., 1998; 51. Lim et al., 2007; 52. Nakata et al., 1998
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nation of the role of certain genes in diseases and pathologies. 
especially the availability of meSC with reporter constructs has 
been broadly applied to high-throughput screens, e.g. for com-
pounds affecting DNt (Suter and Krause, 2008; Suter et al., 
2009; Conti et al., 2005). Similar reporter constructs have been 
introduced and used in heSC or iPSC, but there is still ample 
room for further development and improvement.
3.1.5  Pluripotency status and capacity to form any 
neural cell 
the use and culture of eSC is a demanding technology requir-
ing high standards of good cell culture practice. the lack of 
standardised protocols used for cell differentiation appears to 
be a main source of low reproducibility. Additionally, at present 
no single marker can indicate conclusively that a cell has left 
the developmental status of meSC or heSC and that this cell 
may therefore not be suitable for DNt testing any longer. Only 
groups of markers can be used (tab. 1). Similar questions ap-
ply when iPSC are generated but need to be evaluated for their 
“real” pluripotency. this practical problem is illustrated by data 
shown in Figure 1. the cells from different passages (meSC, 
CGR8 strain) behaved similarly when they were maintained in 
culture (similar growth rate and morphology). Only when the 
differentiation potential was tested did dramatic differences be-
come	obvious.	Similar	findings	 have	been	 reported	 for	 hESC	
that expressed similar levels of a small set of markers (Nanog, 
Oct4, tdgf1) but had dramatically different differentiation po-
tentials (Osafune et al., 2008).
highly synchronised cells and therefore less experimental noise. 
Ideally, many different test systems will be used to optimally 
test potential DNt during all important phases of nervous sys-
tem	development	with	high	sensitivity	and	specificity.
3.1.3  Culture quality
the particular setup of the cultures is a major factor for the suc-
cess of a DNt test system, independent of the endpoint chosen. 
Therefore	we	will	just	briefly	list	some	of	the	factors	that	may	
be important for transcription markers in eSC-based systems. 
Some cultures are grown on feeder cells, which might affect 
the pattern of RNAs detected as well as the differentiation proc-
ess and the effect of chemicals on the overall culture system. 
Similarly,	undefined	components	of	 the	culture	medium,	anti-
biotics or the adhesion matrix might have complicating effects. 
Most importantly, the quality of the cells is a major factor for 
the	experimental	outcome.	The	most	serious	deficiency	of	a	test	
system would be infection or genetic alteration. However, also 
mycoplasma-free, genetically intact cells may be altered epige-
netically, and this may be a major source of experimental vari-
ation (Fig. 1). Only frequent and stringent controls and efforts 
to avoid uncontrolled factors as listed above can lead to robust 
experimental test systems.
3.1.4  Genotype 
In the 21st century we can begin to ask whether there is an inter-
action of genetic and environmental factors (gene x environment 
effect) for DNt and whether our test systems could also yield 
such	information	and	identify	groups	specifically	at	risk.	For	ex-
ample, heSC from different ethnicities, genders and genotypes 
can now be compared. New opportunities have arisen from the 
general availability of the technique to generate human induced 
pluripotent stem cells (hiPSC), which behave like heSC but can 
be generated from presumably all somatic cell types including 
skin samples of individuals. Soon, libraries will be available 
of	human	 iPSC	with	defined	genetic	 defects	 occurring	 in	hu-
man	diseases	and	with	allelic	variations	as	 identified	 in	many	
human individuals. the use of such cells for more genotype-
related information in safety sciences appears very attractive. 
the murine counterpart is the availability of over 20,000 gene 
trapped	mESC	lines	(defined	reporter	insertions	at	intron-exon	
boundaries that may be further genetically engineered e.g. to 
generate transgenic reporter or selection lines for many endog-
enous promoters) (Singla et al., 2010) and of thousands of trans-
genic and knock-out mice with the corresponding meSC de-
rived therefrom. Such meSC may be generated by targeting of 
the second allele of heterozygous knock-out meSC (Madan et 
al., 2009) or from the mice in two different ways. traditionally, 
meSC would be derived from blastocysts of homozygous mat-
ings.	This	process	has	been	greatly	 simplified	 lately	by	 small	
molecule chemicals that support meSC generation (Ying et al., 
2008; li and Ding, 2009). An emerging technology promises 
the generation of pluripotent stem cells from cells of mice by 
different techniques of reprogramming (lewitzky and Yamana-
ka, 2007; Kim et al., 2009a; Stadtfeld et al., 2010; Carey et al., 
2010). transgenic approaches, that also allow expression of hu-
man proteins in mice, have already been applied to the exami-
Fig. 1: Different neuronal differentiation potential of mESCs 
from the same strain. 
CGR8 mESC were kept under routine culture conditions (details 
available from Leist lab). High (passage 115, p115) and low 
(passage 39, p39) passage cells were triggered to differentiate 
towards the neuronal lineage in parallel. After 20 days of 
differentiation, total mRNA was extracted and analysed by 
quantitative real time PCR for marker genes of mESC (Oct4),  
NSC (Nestin) or neuronal (βIII Tubulin, MAP-2, Synaptophysin). 
Gene expression levels were first normalised to the housekeeping 
gene GAPDH and then to the expression in undifferentiated 
mESCs (day 0), which was arbitrarily set to 1. Data represent 
means ± SD from triplicates. *** p < 0.001
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predictor of teratogenicity (Marx-Stoelting et al., 2009; Seiler et 
al., 2006; Genschow et al., 2004; laschinski et al., 1991). the 
biological	test	system	uses	in	this	case	mESC	and	murine	fibro-
blasts under different growth and differentiation conditions, one 
of	them	being	a	relatively	non-specific	differentiation	of	mESC	
to	cardiomyocytes.	The	test	procedure	is	defined	by	INVITTOX	
PROtOCOl no. 113 (DB-AlM data base; http://ecvam-dbalm.
jrc.ec.europa.eu/). the presence of foci of beating cells is the end-
point for cardiac differentiation. the prediction model involves 
mathematical comparisons between different endpoints (e.g. 
IC50	of	 the	cytotoxicity	 to	fibroblasts	and	altered	efficiency	of	
cardiac	differentiation),	classification	of	the	potential	results	and	
translation of these classes into potential human toxicity classes. 
As evident from this example, each of the three main elements 
can be developed and optimised relatively independently from 
the others. A number of developmental neurotoxicants are also 
identified	in	this	assay,	presumably	due	to	their	broad	teratogenic	
potential (Chapin and Stedman, 2009; Buesen et al., 2009).
For the validation of each test system, three major domains 
need to be considered (Hartung et al., 2004; Hoffmann and Har-
tung, 2006): 
3.2.1 Reproducibility
this includes parameters like robustness of the test system, 
comparability of data obtained in different laboratories or by 
different operators, on different days or in parallel replicates. It 
is related to technical features of the assay.
3.2.2 Predictivity
the correlation of the in vitro results with the known human data 
or a corresponding “gold” standard (often in vivo animal data). 
Predictivity	can	be	fine	tuned	by	changes	in	the	biological	system,	
the test procedure or the prediction model. However, it remains 
in the end a mathematical-correlative exercise, which neither re-
quires, nor indicates, relevance. Correlations may also be gener-
ated easily by simple mathematical tricks (Fig. 7 in leist et al., 
2008c).	The	definition	of	predictivity	on	the	basis	of	correlations	
has some implicit consequences. As the set of compounds used 
for the correlations is necessarily small, compared to all possible 
compounds that may be used in the test system, it may not be 
representative to the same degree for all classes of compounds. 
therefore, the prediction model has a certain applicability do-
main, e.g. it applies to a certain group of compounds used for the 
validation process (e.g. genotoxic carcinogens for the Ames test). 
It may fail completely when different compounds (e.g. epigenetic 
carcinogens in the above example) are used.
3.3.3 Biological relevance 
For the above reason, this third domain is highly desired in a 
test system. It has been given less priority than the two other 
domains	in	the	development	of	the	first	generation	of	alternative	
methods. With the rise of the tox21c idea, this should become 
the dominant domain in the near future. Biological relevance 
should be the basis of predictive systems biology. this has a 
major impact on the design of new test systems for DNt.
The	EST	would	be	considered	a	first	generation	test	system	
optimised for predictivity based on correlation. With respect 
It has been shown beyond doubt that intact meSC have the full 
potential of a pluripotent stem cell, i.e. to generate every cellular 
phenotype (including every neural cell) in the organism. If DNt 
assays were to be developed on the basis of heSC, one objection 
may be that formation of complete brains has not been demon-
strated.	Both	for	scientific	and	ethical	reasons	this	ultimate	proof	
of pluripotency is unlikely ever to be provided. However, many 
relevant neural cell types can be formed from heSC. For instance, 
cells derived from heSC have been used for transplantation into 
brains	of	immunodeficient	mice	and	integrated	functionally	(La-
flamme	et	al.,	2007;	Elkabetz	et	al.,	2008;	Koch	et	al.,	2009;	Sharp	
et al., 2009). Also, 3-dimensional “brain-like” engineered neural 
tissue (eNt) has been generated in vitro from heSC (Preynat-
Sauve, 2009). thus it appears that heSC should be also suitable 
as a test system to cover the full range, or at least most aspects, of 
DNt once simple and robust protocols and a full characterisation 
of the functionality of resultant cultures are available.
3.1.6  DNT specific processes and endpoints
Neurodevelopment is a highly complex biological process that 
involves proliferation, migration, apoptosis, differentiation, syn-
aptogenesis, neurite and network formation, as well as gliogen-
esis and myelinisation. All these processes need not only to be 
functional, but also require correct timing and complicated bal-
ances within a microenvironment often referred to as a “niche”. 
Therefore,	one	single	type	of	endpoint	is	unlikely	to	be	sufficient	
for a comprehensive description of the overall outcome. experi-
mental endpoints that have been tested comprise electrophysiol-
ogy, neurotransmitter release, immunostaining and other methods 
of	protein	quantification	including	several	proteomics	techniques,	
methods	 of	 RNA	 quantification,	 functional	 cellular	 assays	 and	
evaluations of cellular morphology. In general, endpoints that 
have been shown to be suitable for other cellular test systems 
should also be useful for meSC or heSC. However, there can be 
practical limitations. these are mainly due to the heterogeneity of 
the	cultures,	which	precludes	certain	methods	of	quantification.	
this heterogeneity may be desired, e.g. for generation of “organ 
simulating tissues”. In most cases it is accidental or stochastic, 
as currently-used protocols lead to the generation of different 
cell populations that are not homogeneously distributed but may 
rather grow in patches or islands within a dish. Moreover, some 
cells grow preferentially on top of or under other cells. In this situ-
ation it is particularly important to select endpoints that guarantee 
robustness (reproducible results, also when experimental condi-
tions vary slightly), are biologically plausible and allow optimal 
predictivity. It is beyond the scope of this review to evaluate the 
usefulness of all different endpoints for DNt testing, and the ex-
perimental evidence for this. Instead, general principles of assay 
set-up will be discussed below in more detail for embryonic stem 
cell-based developmental neurotoxicity testing (eSDNt) testing. 
3.2  In vitro DNT testing and validation:  
ESDNT V1.0 vs. ESDNT V2.0
every in vitro toxicity test system consists of three elements: 
the biological system, the endpoint/test procedure and the pre-
diction	model.	This	is	exemplified	by	the	already	validated	and	
well-established embryonic stem cell test (eSt) used as a general 
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the eSt may be adapted in different ways for DNt testing. 
However, in all cases a fundamental difference between cardio-
teratogenicity and neuroteratogenity needs to be considered: the 
heart consists of a limited number of cell types in a relatively 
homogeneous tissue arrangement, and most developmental ef-
fects on the heart have some form of histological or morpho-
logical correlate. the nervous system consists of many different 
cell populations, and DNt, as well as many CNS diseases, can 
have predominantly behavioural and functional consequences 
(e.g. on regulation of mood, intelligence, attention, concentra-
tion, motor activity) without obvious morphological correlates. 
this needs to be taken into account when test systems are be-
to	neurally-active	 teratogens	(DNT	field)	 it	may	be	called	an	
eSDNt V1.0 (embryonic stem cell based developmental neu-
rotoxicity test, version 1.0). It operates predominantly as a 
black box system, similar to reproductive toxicology studies 
in animals. Understanding of the mechanisms is not required 
to derive the results and the regulatory consequences in both 
positive	or	negative	cases.	Moreover,	and	it	is	difficult	to	ob-
tain information from this system on why positive compounds 
are positive and why negative compounds are negative. How-
ever, as this information is not required for regulatory testing 
of	chemicals,	a	good	correlation	was	sufficient	for	successful	
validation.
Tab. 2: Neural stem cell markers*
 
name accession number full name comment
A230098A12Rik NM_175485 Prtg protogenin homolog transient neuroepithel. progenitor
Ascl1 NM_008553 Mash 1 
Atoh1 NM_007500 Math1 
Bmi1 NM_007552 Polycomb complex protein BMI-1 important for proliferation
Calcr NM_007588a) Calcitonin receptor 
Cdh2 NM_007664 N-cadherin 
Chd1 NM_007690 Chromodomain-helicase-DNA-binding prot. 1 
Chrdl1 NM_001114385b) Chrodin like protein 1 
Crabp2 NM_007759 Cellular retinoic acid-binding protein 2 
CtnnB1 NM_007614 Catenin beta-1 
Cxcr4 NM_009911 C-X-C chemokine receptor type 4 adult and foetal NSC, signalling
Cyp24A1 NM_009996 Vitamin D-hydroxylase 
Dbx1 NM_001005232 Developing brain homeobox protein 1 also adult NSC 
Dbx2 NM_207533 developing brain homeobox 2 
Dll3 NM_007866 Delta-like protein 3 foetal NSC; Notch ligand
EfnB2 NM_010111 Ephrin-B2 assoc. with nestin
Fabp7 NM_021272 Fatty acid-binding protein, brain especially RG
Fgf5 NM_010203 Fibroblast growth factor 5 neurectoderm
Fgfr2 NM_201601c) Fibroblast growth factor receptor 2 
FoxB2 NM_008023 Forkhead box protein B2 very early
FoxD3 NM_010425 Forkhead box protein D3 
Frzb1 NM_011356 frizzled-related protein 
 Fzd1 NM_021457 Frizzled-1 Shh signalling
Fzd3 NM_021458 Frizzled-3 Shh signalling
Gata2 NM_008090 Endothelial transcription factor GATA-2 
Gpr23 NM_175271 lysophosphatidic acid receptor 4 
Gsh2 NM_133256 GS homeobox 2 
Hes5 NM_010419 Hairy and enhancer of split 5 Notch-target
Hes6 NM_019479 Hairy and enhancer of split 6 Notch-target
Id2 NM_010496 Inhibitor of DNA binding 2 BMP/TGF pathway
Ireb2 NM_022655 Iron-responsive element-binding protein 2 
Lhx1 NM_008498 LIM/homeobox protein Lhx1 
Lhx9 NM_001025565d) IM/homeobox protein Lhx9 
Lrp NM_008512 low density lipoprotein receptor-related protein 
Mbnl NM_020007 muscleblind-like 1 
Meis1 NM_010789 Myeloid ecotropic viral integration site 1 
Metrn NM_133719 Meteorin also astrocytes
Msi1H NM_008629 Musashi 1 RNA-binding
Msx1 NM_010835 Msh homeobox 1-like protein inhibits neuronal differentiation
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 name accession number full name comment
Nedd9 NM_001111324e) Enhancer of filamentation 1 
Nes NM_016701 Nestin Gold standard, broad profile
NeuroD4 NM_007501 Neurogenic differentiation factor 4 
Nfe2L2 NM_010902 Nuclear factor erythroid 2-related factor 2 
Nhlh2 NM_178777 Helix-loop-helix protein 2 
Notch1 NM_008714 Notch 1 
Nr2F1 NM_010151 COUP transcription factor 1 
Nr6A1 NM_001159548f) Nuclear receptor subfamily 6 group A memb 1 
Ntrk3 NM_008746g) NT-3 growth factor receptor 
Numb NM_001136075h) Protein numb homolog 
Otop1 NM_172709 Otopetrin-1 
Otx2 NM_144841 Orthodenticle homolog 2 
Pax3 NM_008781i) Paired box protein Pax-3 also in some cells at later stages
Pax6 NM_013627 Paired box protein Pax-6 also at later stages
Prkcz NM_008860 j) Protein kinase C zeta 
Prom1 NM_008935 Prominin-1, CD133 also other (haematopoietic) SC
Pxmp3 NM_008994k) Peroxisome assembly factor 1 
Ror2 NM_013846 Tyrosine-protein kinase transmembrane R. membrane receptor
Rtn1 NM_153457l) Reticulon-1 
Runx1 NM_001111022m) Runt-related transcription factor 1 
Rxra NM_011305 Retinoic acid receptor RXR-alpha 
Ryr3 NM_177652 ryanodine receptor 3 
Sema5b NM_013661 Semaphorin-5B 
Sfrp2 NM_009144 Secreted frizzled-related protein 2 
Sox1 NM_009233 Transcription factor SOX-1 
Sox11 NM_009234 Transcription factor SOX-11 in foetal NSC
Sox2 NM_011443 Transcription factor SOX-2 also in ESC
Tal2 NM_009317 T-cell acute lymphocytic leukemia protein 2  
Tcf4 NM_013685n) Transcription factor 4 
Tnnc2 NM_009394 Troponin C 
Wnt5a NM_009524 Protein Wnt-5a 
Wnt8b NM_011720 Protein Wnt-8b 
Zic1 NM_009573 Zinc finger protein 1 
RG: radial glia; NSC: neural stem cells; OG: oligodendrocytes; SC: stem cells
Additional accession numbers:  
a) NM_001042725, b) NM_031258, c) NM_010207, d) NM_001042577, NM_010714, e) NM_017464,  
f) NM_010264, NM_001159549, g) NM_182809, h) NM_010949, i) NM_001159520, j) NM_001039079, k) NM_008994,  
l) NM_001007596, m) NM_009821, NM_001111021, NM_001111023, n) NM_001083967
* Abranches et al., 2009; Maisel et al., 2007; Kelly et al., 2009; Vogel et al., 2009; Gaspard et al., 2008; Liu et al., 2004;  
Barberi et al., 2003; Ghosh et al., 2008
to	be	insufficient	for	DNT	test	systems.	More	refined	endpoints	
that describe neuronal subpopulations and differentiation states 
are required. the use of RNA-based markers is suggested here 
as one possible approach to be explored.
Moreover, to make the test systems independent of narrow 
applicability domains and to design them for broad testing right 
from the start, the tox21c strategy suggests a toxicity pathway 
and mechanism-based approach (NRC, 2007). Such assays 
would examine quantitative cause-effect relationships with ref-
erence to relevant toxicity pathways, and the prediction model 
would integrate the rich information from multiple endpoints. 
Such future assay systems may then be labelled eSDNt V2.0. 
ing developed. For instance, the difference in the ratio between 
different neuronal populations needs to be detectable in the ab-
sence of an overall loss of cells. As different brain regions de-
velop during different time windows, they display different sen-
sitivities to neurotoxicants at different times. For instance, the 
DNt compound methylazoxymethanol (MAM) has different 
effects on the brain when given on different days of embryonic 
development (Penschuck et al., 2006 and references therein). 
thus DNt test systems must also provide the option to apply 
potential toxicants in different phases of development.
Simple endpoints (for instance the number of all neurons or of 
functional neurons – similar to those used in the eSt) are likely 
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from a non-homogeneous mixed cell population and can give 
information on its relative composition. the transcriptional 
profiling	 approach	 has	 particular	 advantages	 for	 quantitative	
studies in inhomogeneous populations of adherent cells or for 
complex	mixtures	of	cells,	if	appropriate	cell	specific	markers	
and reference genes are available (see below – point (3)). the 
big disadvantage of the technology is that co-localisation stud-
ies	are	not	readily	possible,	and	therefore	the	specific	cell	sub-
population that undergoes changes in response to the toxin can 
be	difficult	to	identify.	
the use of transcription based endpoints (e.g. Northern blot, 
gene microarrays and PCR) also requires some technical con-
siderations,	 as	briefly	 summarised	 in	Tab.	3.	Microarray	plat-
forms may indicate relative expression differences with varying 
sensitivities and accuracies for different genes. Without detailed 
background data, information on a single gene may not be reli-
able.	As	an	alternative,	sets	of	interesting	cell-	or	state-specific	
genes	can	be	selected	for	detailed	quantification	of	relative	gene	
expression changes by quantitative real-time PCR methods. If 
profiling	 is	performed	by	PCR	on	a	selected	set	of	genes,	 the	
technology is available in most laboratories at reasonable cost 
and	throughput,	and	optimised	primers	for	amplification	can	be	
derived from online databases (RtPrimerDB, http://medgen.
ugent.be/rtprimerdb/).
As this review focuses on the compilation of gene lists that 
should be useful as background description of cellular states in 
DNt assays, three major technical issues of gene selection and 
classification	will	be	discussed:	
4.1.1  Gene annotation
First, the literature, including also relatively recent publications, 
is	filled	with	strongly	varying	abbreviations	for	one	given	gene.	
this is due to the discovery and cloning process, which often 
occurred in parallel in different places, initial discovery in dif-
ferent species, protein and antigen names that differ from the 
Here an initial basis is provided for the characterisation of the 
cells used in such assays.
4  The definition of stem cell genes
4.1  Transcription-based markers
For	the	definition	of	cell	types	and	of	transitions	from	one	cell	
type to another, different sets of markers may be applied. these 
range	from	definition	of	the	genome	(primary	sequence	and	epi-
genetic	status)	to	definition	of	the	proteome	(protein	based	or	an-
tigen-based), and include the metabolome, functional character-
istics (e.g. electrophysiological responses) and characterisation 
of the transcriptome (mRNAs and miRNAs). these approaches 
have	different	sensitivities,	dynamic	ranges,	specificities,	sam-
ple requirements, technical requirements and throughput. 
the most frequently used approaches are antigen based meth-
ods	 and	 transcriptional	 profiling.	The	 former	 have	 been	 dealt	
with	elsewhere,	and	extensive	studies	in	the	stem	cell	field	have	
been performed e.g. by BD Biosciences (www.bdbiosciences.
com).	Briefly,	they	are	particularly	useful	for	single	cell	charac-
terisation and for sorting cells, only limited by antibody avail-
ability (works best for surface antigens). Quantitative evalua-
tions	by	this	approach	usually	involve	flow	cytometric	analysis	
and work particularly well in non-adherent cultures or with cells 
that can be detached by enzymatic treatment without affecting 
the epitope. Use on adherent cells requires advanced imaging 
technologies and is often harder to quantify and to control. On a 
semi-quantitative or qualitative level, antigen staining offers an 
easy option to characterise mixed cell populations and to deter-
mine co-localisation of different markers within a given cell. 
RNA-based measurements have been suggested to be par-
ticularly useful to characterise the differentiation of eSC 
(Noaksson et al., 2005) and to detect neurotoxicity and DNt 
(Hogberg et al., 2009; Bal-Price et al., 2009; Stummann et al., 
2009).	Transcriptional	profiling	has	been	used	in	many	fields,	
for instance to indicate cellular activation states (Henn et al., 
2009; lund et al., 2006; Falsig et al., 2006). the method is fre-
quently used successfully for quantitative studies in homogene-
ous populations of cells. More or less every gene transcript can 
be examined (few exceptions due to highly repetitive or highly 
GC-rich sequences). the expression pattern can be interpreted 
as a “signature” of the status of the tested cell population. the 
“signature”	 can	 be	 examined	 in	 terms	 of	 known	 cell	 specific	
markers,	gene	ontology	(GO)	classification	systems	and	known	
gene interaction networks. For instance, different types and 
differentiation stages of neurons and glial cells differ in their 
RNA	profiles,	and	these	profiles	differ	from	that	of	ESC	(Tab.	
1)	or	neural	stem	cells	(NSC	–	Tab.	2).	Therefore,	definition	of	
reference	profiles	for	different	culture	states	should	permit	the	
detection of subtle effects of developmental neurotoxicants and 
give information on the affected pathways. Deviations from the 
“default transcription signature” may permit the detection of 
subtle effects of developmental neurotoxicants, and give infor-
mation as to the pathways affected. they may also occur as 
a consequence of cell cycle progression or cellular activation 
state. Such signatures and their alterations can also be obtained 
Tab. 3: Issues concerning identification and selection  
of transcription-based markers
Definition of applicability domain
Selection of criteria for appropriate markers (assay dependent)
Method for identification/qualification of markers
Selection of negative (exclusion) and positive markers
Assembly of set of markers (no single marker is adequate)
(Semi-)Quantitative relationship of markers 
(ratios; thresholds; yes/no)
Definition of differentiation status
Composition of culture over time 
Selection of control population(s) for cell type specific endpoints
Biological validation of endpoint-markers with (positive and 
negative) controls
Timing of chemical exposure (duration and differentiation status)
Use of reference databases for cross-validation of data
Statistical and standardisation issues within and between 
experiments
Known species differences
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GO	does	not	exist,	as	GOs	do	not	define	cell	types,	but	rather	
related functions of genes. therefore meSC genes as endpoints 
of	DNT	tests	need	to	be	defined	and	agreed	upon	as	in	Table	1.
 
4.1.3  Standardisation and statistical issues
They	can	strongly	influence	the	identification	of	marker	genes.	
this applies in different ways to individual studies as well 
as to meta-analyses. In the former, normalisation, standardi-
sation and cut-off procedures are mostly hidden in materials 
and methods in a way that makes them hard to control or to 
reproduce by peers. Alterations of expression levels are often 
calculated relative to housekeeping genes, but the stability and 
variance of these reference points is only very rarely indicat-
ed. However, these data and procedures have a large impact 
on	 specificity	 and	 sensitivity	 of	 the	 overall	 analysis.	 House-
keeping genes may be selected based on various criteria. Most 
importantly, the gene needs to be expressed in equal amounts 
relative to the total amount of cellular mRNA. In many cell 
types,	this	condition	is	fulfilled	for	Gapdh, 18S ribosomal RNA 
(18S rRNA), and β2 microglobulin (b2m). Other markers that 
are also used frequently comprise Hprt, 28S ribosomal RNA 
(28S rRNA), Actb or Acta1. More rarely found options are 
Ribosomal protein L32 (RPl32) or Phosphoglycerate kinase 
1 (PGK1). However, these housekeeping mRNAs do not al-
ways behave according to the criteria set above (e.g. Der et al., 
1998). this problem is particularly pronounced in differentia-
tion	experiments,	as	described	here.	In	this	case,	the	final	cell	
type in the dish can be very different (overall phenotype, size, 
cell cycle status, metabolic activity, etc.) from the starting cell, 
and therefore express housekeeping genes at different levels. 
Similar problems may occur upon exposure to toxicants. An-
other type of problem lies in the heterogeneity of cells in DNt 
test systems. the cultures may contain different subpopulations 
that express house-keeping genes at different levels. Upon dif-
ferentiation, the relative amounts of these subpopulations may 
change dramatically, leading to enormous practical challenges 
concerning the standardisation of gene expression levels. to 
circumvent this, samples are often referenced to a group of 
housekeeping genes instead of a single gene only. In other cas-
es,	it	may	be	useful	to	employ	subpopulation-specific	reference	
points, such as B3 tubulin or Fox-3 (NeuN) for neurons, and 
e.g. Doublecortin or Neurogenin to refer shifts in patterning 
markers	more	 specifically	 to	 neuroblast-like	 cells	 within	 the	
overall population. Concerning meta-analysis (e.g. Assou et al., 
2007; International Stem Cell Initiative, 2007; Bhattacharya et 
al., 2005; Bhattacharya et al., 2009), additional problems need 
to be considered. the statistical criteria and quality of the stud-
ies included in the meta-analysis might vary strongly, and the 
initial conditions and rules set within these analyses might be 
hard to trace. therefore, it is dangerous to rely blindly on the 
summary of the outcome. this applies also to the table compi-
lations presented here. If they are put to experimental scrutiny 
and trigger a constructive discussion and an improved second 
version, then a major goal of this review will already have been 
reached. Possibly subsets will have to be selected, according 
to	 the	 specific	 culture	 conditions	 and	 cell	 lines	 used	 and	 the	
questions asked.
gene name, and changes of names upon consolidation of the 
fully sequenced mouse and human genomes. We have chosen 
to	 include	 the	currently-used	official	gene	symbol	 that	can	be	
retrieved from PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 
in addition to various other names in common use. In addition, 
the	transcript	accession	number	(as	an	unambiguous	identifier)	
is listed. Notably, these accession numbers do not refer to the 
genes	as	 such,	but	define	cDNAs.	They	may	e.g.	characterise	
particular transcripts of genes with multiple splicing variants. 
thus, one gene can have more than one accession number. this 
is highly important for expression analysis and corresponding 
database searches, as a given gene can form different transcripts 
in different cell types or at different differentiation stages. 
therefore, problematic situations might arise where analysis of 
gene regulation by different methods (different PCR primers, 
different hybridisation oligos, etc.) yields different results. In 
such situations, different transcripts might have been analysed. 
to cover this situation, accession numbers for different splice 
and annotation variants of the same gene are also included in the 
tables. the NCBI RefSeq database provides annotated individu-
al transcripts and protein sequences (derived from its predeces-
sor, Genbank) with accession numbers that are distinguished 
by	 a	 two-letter	 prefix	 (http://www.ncbi.nlm.nih.gov/RefSeq/
key.html). Curated transcripts for mRNA, noncoding RNA and 
protein	sequences	are	distinguished	by	the	prefixes	NM_,	NR_,	
and	NP_,	respectively.	Other	prefixes	indicate	original	Genbank	
annotations	 (two-letter	 prefixes	 without	 a	 following	 under-
score) or Refseq sequences that are undergoing annotation or 
curation	(Typically	XM_,	XR_,	XP_)	among	others.	Ensembl,	
an alternative informative annotation and curation effort by the 
european Bioinformatics Institute (eBI) also curates sequences 
and splice variants derived thereof (www.ensembl.org). typi-
cally, it is helpful to design gene expression strategies against 
the curated sequences, although it is important to be aware of 
(and design around) the potential for underlying variation in that 
transcript. the collective variation in gene expression can be 
viewed with the aid of online genome browsers as provided by 
the University of Santa Cruz (http://genome.ucsc.edu/) or the 
eBI (http://www.ensembl.org/index.html).
4.1.2  GO categories
When	large-scale	transcriptional	profiling	is	performed,	identi-
fied	genes	are	often	associated	with	gene	ontologies	(GO).	The	
Gene Ontology Project is an initiative to classify genes and 
gene products according to known molecular functions with a 
defined	 and	 finite	 vocabulary	 (http://www.geneontology.org).	
GO	classifications	associate	gene	products	with	appropriate	cat-
egories in the three principal areas “cellular component”, “bio-
logical process”, and “molecular function”. they are organised 
by a hierarchical relationship between these groups. When the 
transcriptional	profile	of	a	cell	population	changes,	the	altered	
transcripts often cluster to certain GOs, and these GOs can give 
useful information on the types of changes that are occurring 
(structural, signalling, differentiation). thus, it may be useful 
to	pick	the	genes	of	a	hypothetical	“mESC	GO”	to	define	the	
starting population of DNt experiments and the changes of 
genes characteristic for this population. Unfortunately such a 
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2007). In addition, much of the variation may be due to real spe-
cies differences. In fact, the biology of meSC and heSC shows 
distinct differences with regard to signals required to maintain 
pluripotency (Wei et al., 2005; eckfeldt et al., 2005; Wang et al., 
2009). In this situation, it is tempting to conclude quickly that 
heSC are more relevant for human physiology. However, strong 
evidence indicates that meSC may resemble cells of the human 
inner cell mass of the blastocyst more closely than heSC (li and 
Ding, 2009). Moreover, it is not known whether some differences 
of eSC in culture have any effects on readouts for DNt. this can 
only be determined experimentally, and should be done so.
The	overall	approach	of	differential	transcription	profiling	to	
identify eSC markers has some conceptual shortcomings: First, 
the factor of differential expression that is used as cut-off is often 
relatively low (e.g. 2-3 fold). this means that it would be very 
hard to identify an eSC contamination of around 30% within 
an otherwise fully differentiated cell population. this low cut-
off	also	reduces	the	level	of	specificity	such	studies	can	achieve.	
Second, the “differentiated population” used for comparison 
was frequently obtained from embryoid bodies (eBs), i.e. 3-di-
mensional spheroids formed from eSCs when they are left to 
differentiate “wildly” (in a non-guided way, only triggered by 
withdrawal of pluripotency factors). this population contains 
cells from all three germ layers, and may not be relevant for the 
identification	 of	 differentially-expressed	 genes	 between	 ESC	
and differentiating neurons. thirdly, this approach is bound to 
identify many “false positives”, as two populations with differ-
ent proliferation characteristics are being compared. thus, genes 
involved in DNA synthesis, chromatin structuring and cell cy-
cle regulation would be selected as putative stem cell genes. A 
variant of this approach was taken by the International Stem Cell 
Initiative	(ISCI)	to	define	hESC	markers.	Genes	were	grouped	
according to the similarity of their behaviour to that of Nanog 
when over 50 heSC lines were differentiated to eBs. the top 6 
group comprises Nanog, Tdgf1, Gabrb3, Dnmt3b, Gdf3, Pou5f1/
Oct4 and the top 20 group additionally contains Fgf4, Gal, Leftb, 
Ifitm1, Nodal, Tert, Utf1, Foxd3, Ebaf, Lin28, Grb7, Podxl, Cd9 
and Brix (the International Stem Cell Initiative, 2007).
A third approach to identify stem cell genes is based on the 
concept that genes qualify for inclusion when they are required 
for the function and maintenance of eSC. these genes would be 
biologically	defined	as	“stemness	genes”.	This	definition	would	
also form the basis for the opening of a GO category under the 
field	of	“biological	function”.	The	most	prominent	examples	for	
such genes are Pou5f1/Oct4 and Nanog (Mitsui et al., 2003) or 
the Klf (Krüppel-like factor) genes. However, Oct4 is also found 
in germ stem cells or cardiac differentiation (Stefanovic and 
Puceat, 2007), Nanog plays a role in neuronal differentiation 
(Molero et al., 2009) and Klf-4 is also an oncogen (Rowland et 
al., 2005). the Wnt, FGF and BMP/tGF-ß pathways –  and as-
sociated genes – are clearly involved in the maintenance of stem-
ness, but they also play a role in dozens of other processes. the 
same type of ambiguity is found when one examines the genes 
that can be used for reprogramming. In addition to Oct4, Na-
nog and Klf-4 above, for instance Sox2, Lin28 and Myc are used. 
Sox2 and Myc play roles not only in reprogramming but also in 
stem	cell	maintenance.	However,	they	are	not	specific	for	ESCs,	
4.2  What are stem cell genes?
At	first	sight,	it	may	seem	easy	to	extract	stem	cell	genes	from	
the existing literature. Dozens of papers have dealt with such 
genes and large numbers of microarray studies have been per-
formed to identify such genes, but also doubt has been voiced 
on	whether	stem	cells	are	really	a	defined	entity	at	all,	or	wheth-
er they rather represent one of many possible transient states 
(efroni et al., 2009; Zipori, 2004). the expression pattern as-
sociated with such states may vary between different stem cell 
lines. Such effects may be linked to higher dynamics of the 
genome than commonly expected. For instance, non-protein 
coding line elements, which make up a large proportion of the 
human genome, have been shown to be active as transposons in 
eSC and, even more commonly, in NSC. Such activity might 
affect the activity of classical genes directly, e.g. by insertion, or 
indirectly,	by	modification	of	pervasive	transcription	(Coufal	et	
al., 2009; Muotri et al., 2007; Garcia-Perez et al., 2007; Muotri 
and Gage, 2006; Muotri et al., 2005).
For assay development we have to take a closer look at the 
important distinction between “stemness genes” and “stem cell 
marker	genes”.	For	the	specific	purpose	of	this	review,	the	focus	
of the discussion will be on eSC (and NSC) markers.
Unfortunately, the term “stem cell marker gene” is less clear 
upon	closer	inspection	than	it	appears.	An	easy	definition	would	
for instance be “a gene that is only expressed in meSC, and in 
no other cell type”. Unfortunately, no such gene exists. the re-
verse	definition	may	also	be	applied.	“Negative	stem	cell	mark-
ers” are genes that are by no means expressed in meSC. this 
is	a	definition	that	is	useful	in	practice	for	quality	control	and	
for	defining	the	onset	of	differentiation,	but	it	is	not	sufficient	
for	 defining	mESC	 (Assou	 et	 al.,	 2007;	Bhattarachyan	 et	 al.,	
2009).	The	definition	of	 negative	markers	 is	 also	not	without	
ambiguity, as meSC cultures may often be contaminated with 
more differentiated cells. Upon transcriptome analysis it may 
then appear that apparently pure stem cells “express” certain 
genes usually not associated with meSC, such as B3 tubulin, 
Keratins-8 and -18 or Alpha cardiac actin (Ginnis et al., 2004; 
Bhattacharya et al., 2005). to establish an eSC database free of 
contaminations, cells may be sorted prior to analysis or selected 
on the basis of the activity of a sharply-regulated stemness gene 
like Utf-1 (tan et al., 2007).
A	pragmatic	approach	to	the	identification	of	ESC	genes	is	to	
characterise transcriptome changes when eSC differentiate and 
to	define	those	genes	that	are	differentially	highly	expressed	in	
eSC as stem cell genes. this approach has been taken many 
times in many variations (reviewed in Bhattacharya et al., 2009 
and efroni et al., 2009). the result was that these approaches 
consistently	identified	a	small	group	of	“usual	suspect	genes”	for	
eSC, such as Lefty2, Oct3/4, Nanog, Utf-1 and Tdgf1. However, 
astonishingly large differences were observed between the stud-
ies. It was surprising that some studies found that meSC genes 
overlap with heSC genes only to a low degree, i.e. between 15 
and 35% (Bhattacharya et al., 2005; Ivanova et al., 2002; Ram-
alho-Santos et al., 2002). this may indicate some intrinsic weak-
nesses of these studies (see e.g. paragraph on standardisation and 
statistics issue). An alternative explanation may be that the deri-
vatisation of the lines affects their later phenotype (Navara et al., 
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lar	as	for	the	markers	identified	by	expression	level.	Stemness	
genes are not included when their expression is relatively low 
compared to neural tissue expression.
(e) Only mRNAs coding for proteins have been considered for 
this analysis. Information on micro RNAs (miRNA) is still rela-
tively limited. However, it appears that expression of miRNA 
can	 be	 relatively	 cell	 type-specific.	 Thus,	 miRNAs	with	 rela-
tively high expression levels in meSC compared to other cell 
types	may	 be	 identified	 (Lakshmipathy	 et	 al.,	 2007a,b).	 Simi-
larly,	miRNAs	important	for	defined	steps	in	neuronal	develop-
ment	have	been	identified	(Yoo	et	al.,	2009).	Future	profiles	may	
therefore also include miRNAs. A further step may be a more 
detailed analyses of the promoters themselves and their epige-
netic state by chip-on ChIP experiments (microarray analysis of 
chromatin	immunoprecipitates),	bisulfite	sequencing	(identifica-
tion of methylcytosine as altered base in the DNA structure) or 
one of the many related new technologies. For instance, it has 
been suggested that the eSC genome may be characterised and 
defined	by	relatively	open	chromatin	architecture	(Zipori,	2004;	
eckfeldt et al., 2005). this has been corroborated on the mo-
lecular level by genome-wide mapping of the chromatin state 
of eSC and other cells and indeed has functional consequences 
(Mikkelsen et al., 2007). the resultant pervasive transcription is 
particularly prominent in eSC, and a major difference between 
eSC state and more lineage committed differentiation stages may 
be the extent of this genome wide transcriptional activity (efroni 
et al., 2009), that involves many non-protein coding RNAs (Ber-
retta and Morillon, 2009; Dinger et al., 2009; Jacquier, 2009; 
Mikkelsen et al., 2007). to transform this knowledge into robust 
test	endpoints	and	defining	markers,	the	identification	of	ESC-
specific	non-coding	RNA	would	appear	useful.	Indeed,	recently	
over a thousand conserved large intervening non-coding RNAs 
(lincRNAs)	have	been	identified	(Guttman	et	al.,	2009).	About	
100 were regulated by Oct4 and Nanog and functionally impli-
cated in a stemness network, and at least one was only expressed 
in eSC. thus, lincRNAs are candidates for future lists of differ-
entiation	and	cell	activation-defining	lists	of	markers.
(f)	Last,	but	definitely	not	least,	negative	markers	should	be	used	
in transcription-based cell characterisations. the meSC table 
contains only positive markers, as naturally all genes listed in 
table 2 (or other tables presented here) represent the correspond-
ing negative markers. typical markers for endodermal differen-
tiation (e.g. intestine, glands, liver) would be VegfR2, Sox17, Ttr, 
ApoA1, Lim1, Cytokeratin19, FoxA2, Alphafetoprotein or Gata-4 
(also mesendoderm and cardiac mesoderm); for mesoderm (e.g. 
muscles, bones, heart, blood): Hand1, Brachyury, Smooth mus-
cle actin, Cd31, Cd34, Cd325 or Eomes (also trophoblast), and 
e.g. Ncam1 or certain keratins (Krt 18) indicate ectoderm. Other 
useful and sensitive markers for initial differentiation away from 
eSC may be Fibronectin-1, Naalad2, Profilin-1 and Slc40a1.
4.4  Neurodevelopmental biology and definition  
of neural stem cell markers
Differentiation of meSC towards neurons triggers coordinated 
waves	of	gene	transcription	that	can	be	identified	by	unbiased	
cluster analyses (Abranches et al., 2009; Schulz et al., 2009). 
Accordingly, the cells move from the multipotent stem cell state 
as e.g. Sox2 is highly expressed (and functional) in NSCs, and 
Myc is upregulated in many tumours and rapidly dividing cells.
In conclusion, simple rules for the selection of eSC marker 
genes cannot be applied. More advanced algorithms based on 
multiple markers are required as described below.
4.3  Definition of mESC markers
Based	on	 the	above,	markers	were	filtered	 from	 the	 literature	
according to the following criteria: 
(a) the gene needs to be expressed in meSC (differences be-
tween meSC and heSC need to be taken into account).
(b) the gene needs to be expressed in meSC considerably high-
er than in most other cell types. Frequently, eSC were com-
pared to embryoid bodies (eBs). In other approaches meSC 
were compared to mNSC and other stem cell types (haemat-
opoietic) to identify unique marker genes (Ivanova et al., 2002; 
Ramalho-Santos et al., 2002). An interesting approach in that 
direction was also taken by groups at the NIH (Bhattacharya et 
al., 2004; Bhattacharya et al., 2005; Bhattacharya et al., 2009; 
Ginis et al., 2004), when eSC were compared to RNA pools 
from normal differentiated tissue. this approach was taken one 
step further in a large meta-analysis, in which heSC expression 
profiles	were	compared	to	data	retrieved	from	databases	on	over	
100 tissue analyses (Assou et al., 2007). For the compilation of 
table 1, especially co-expression at similar levels in NSC was 
used	as	an	exclusion	criterion.	Notably,	as	mESC	are	defined	by	
a group of genes, the criterion of absence of expression in other 
cells needs not be applied stringently, providing that it refers to 
different	cell	types	for	different	marker	genes.	If	a	sufficiently	
large group of meSC marker genes is selected, it is likely that 
expression in other cells is cancelled out (averaged), while each 
of the genes should be expressed in meSC.
(c) the marker gene should not be expressed in neural stem 
cells and neuroectodermal cells and thus be different from the 
ones	listed	in	Table	2.	This	condition	is	a	specific	limitation	of	
condition 2 and applies particularly for meSC markers used in 
DNt experiments. For instance, Galanin is a frequently-identi-
fied	mESC	gene,	but	also	plays	a	role	in	NSC	and	certain	mature	
neurons. Genes with such behaviour may not be downregulated 
upon meSC differentiation towards the neuronal lineage and are 
therefore useless as meSC markers for this particular purpose. 
A vast amount of gene expression data is available to identify 
relevant genes. Here, both individual papers (e.g. Abranches et 
al.,	 2009)	 and	 databases	were	 used	 for	 identification	 and	 ex-
clusion	 of	 candidates.	 For	 instance,	 the	 EU	 fifth	 framework	
research programme (FP5)-consortium FunGeneS provides 
extensive	 transcriptome	 profiling	 information	 on	 the	 differ-
entiation of meSC to neurons, coupled to web-based analysis 
software (FunGeneS consortium  http://www.fungenes.org/) 
(Schulz et al., 2009). Similar approaches are taken for instance 
by the StemBase of the Ontario Genomics Innovation Center 
(StemBase  http://www.stembase.ca/?path=/) (Perez-Iratxeta 
et al., 2005; Porter et al., 2007).
(d) Genes with a known functional role for the maintenance of 
meSC (e.g. loss of stemness upon their knockdown or knockout 
(Misui et al., 2003)) are included as markers if they do not have 
multiple roles also in other cell types. the reasoning is simi-
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larly,	ESC-derived	NSC-like	 cells	 can	 acquire	 region-specific	
phenotypes depending on the differentiation protocol (Bouhon 
et	al.,	2006;	Gaspard	et	al.,	2009).	Therefore,	not	all	cells	fulfill-
ing basic criteria for NSC can still be differentiated to all CNS 
cell types. Differences also exist between eSC-derived NSC, 
and brain-derived NSC (both can only be obtained by extensive 
in vitro culturing, potentially leading to artefacts), for instance 
in the readiness to generate astroglial cells, or between spinal 
cord NSC and cortical NSC in the expression of many pattern-
ing marks and genes with broadly varying biological function 
(Kelly et al., 2009). thus, it is not a straightforward and unam-
biguous	approach	to	define	NSC	markers	by	characterising	one	
given NSC population that can be maintained in culture. 
Defined	protocols	for	mESC	neuronal	differentiation	typical-
ly	involve	initial	neural	specification	and	expansion	under	NSC	
growth conditions, followed by withdrawal of growth factors 
over an early neuroectoderm state to a state in which they can 
form rosettes that still have the potential to develop to central and 
peripheral neurons. this state is closely linked to the production 
of neural precursor cells or NSC. Such NSCs (human or murine) 
may be enriched and clonally expanded under appropriate cul-
ture conditions (Ying and Smith, 2003; Conti et al., 2005; Bar-
beri et al., 2003; Koch et al., 2009; elkabetz et al., 2008; Okabe 
et al., 1996). NSC markers may be derived from gene expres-
sion	profiling	of	clonally-expanded	NSC-like	cells.	This	has	for	
instance been done for human rosette-type cells vs. heSC (elk-
abetz et al., 2008), but multiple comparisons against different 
populations (including more mature neurons) would be required 
to	define	the	genuine	NSC	genes.	NSCs,	while	sharing	common	
properties of undifferentiated progenitors, may exhibit distinct 
regional	capacities	for	neural	differentiation	to	specific	lineages	
or neurotransmitter phenotypes (Klein and Fishell, 2004). Simi-
Tab. 4: Markers for fine mapping of DNT effects in developing neural cells
category name accession number full name comment
rostral-caudal FoxG1 NM_008241a) forkhead box G1 (Bf1) very rostral
 Emx1 NM_010131 empty spiracles homolog 1 very rostral
 Emx2 NM_010132 empty spiracles homolog 2 forebrain
 Dlx1 NM_010053 distal-less homeobox 1 forebrain
 Nkx2.1 NM_009385 Titf1, NK2 homeobox 1 forebrain
 Gsx2 NM_133256 GS homeobox 2 forebrain
 En1 NM_010133 engrailed 1 midbrain
 Otx1 NM_011023 orthodenticle homolog 1 dorsal fore- and midbrain
 Otx2 NM_144841 orthodenticle homolog 2 dorsal fore- and midbrain
 Atoh1 NM_007500 Math1, atonal homolog 1 hindbrain
 Irx3 NM_008393 Iroquois related homeobox 1 caudal
 HoxA2 NM_010451 Homeobox A2 rostral hindbrain
 HoxB1 NM_008266 Homeobox B1 rostral hindbrain
 HoxB4 NM_010459 Homeobox B4 caudal hindbrain
 HoxB6 NM_008269 Homeobox B6 spinal cord
dorsal-ventral Shh NM_009170 sonic hedgehog ventral 
 Gli3 NM_008130 GLI-Kruppel family member dorsal forebrain
 Olig2 NM_016967 OC transcription factor 2 hindbrain
 Isl1 NM_021459 ISL1 transcription factor forebrain
 Nkx2.2 NM_010919b) NK2 transcription factor ventral
 Neurog2 NM_009718 neurogenin 2 dorsal forebrain
 Nr2f1 NM_010151 nuclear receptor subfamily 2 ventral forebrain
 Ascl1 NM_008553 Mash1, achaete-scute complex homolog 1 ventral forebrain
 Msx1 NM_010835 homeobox msh-like 1 ventral midbrain
 Dll1 NM_007865 delta-like 1 ventral midbrain
neuronal subtypes GAD2 NM_008078 glutamic acid decarboxylase 2 GABAergic neurons
 Gat3  NM_144512 solute carrier family 6a13 GABAergic neurons
 Calb1 NM_009788 calbindin 1 GABA subtypes
 Calb2 NM_007586 calbindin 2, calretinin GABA subtypes
 TH NM_009377 tyrosine hydroxylase dopaminergic neurons
 VGlut2  NM_080853 solute carrier family 17a6 glutamatergic neurons
 Adra2b NM_009633 adrenergic receptor adrenergic neurons
 Tph1 NM_009414 tryptophan hydroxylase 1 serotonergic neurons
 Chat NM_009891 choline acetyltransferase motor neurons
 Mnx1 NM_019944 HB9, motor neu. And panc. homeobox 1  motor neurons
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category name accession number full name comment
NCC Sox10 XM_128139 SRY-box containing gene 10 transcription factor
neuroblast Dcx NM_010025c)  Doublecortin cytoplasmic protein
 NeuroD4 NM_007501 neurogenic differentiation 4 transcriptional activator
 Tubb3 NM_023279 tubulin beta 3 cytoskeleton protein 
 Elavl4 NM_010488d) emb. lethal abnormal vision-like 4  RNA binding protein
 Epha7 NM_010141e) Eph receptor A7 growing axons
non ectodermal germ layers Sox17 NM_011441 SRY-box containing gene 17 mesoderm
 Acta2 NM_007392f) SMA, actin, alpha 2, smooth muscle mesoderm
 T NM_009309 Brachyury mesoderm
 Gata4 NM_008092 GATA binding protein 4 endoderm
 Afp NM_007423 alpha fetoprotein endoderm
ECM components Col4a1 NM_009931 collagen type IV alpha 1 early marker in diff.
 Ncan NM_007789g) Neurocan early marker in diff.
 Tnc NM_011607 tenascin C late marker in diff.
 Col1a1 NM_007742 collagen type I, alpha 1 late marker in diff.
neuronal marker Syp NM_009305 Synaptophysin synaptic vesicle assoc.
 Grin1 NM_008169 NMDA1 ionotropic glutamate R.
 Nrg1 NM_178591 neuregulin 1 schiz. assoc.
 Nrxn 1 NM_020252 neurexin I autism, schiz. assoc.
 Stx1a NM_016801 syntaxin 1A synapse assoc.
 Snca NM_009221h) Synuclein alpha parkinson assoc.
 Mapt NM_010838i) microtubule-associated protein tau alzheimer assoc.
OC: oligodendrocyte, panc: pancreas, neu: neuron, NCC: neural crest cell, emb: embryonic, R: receptor, schiz: schizophrenia,  
assoc: associated 
Additional accession numbers: a) NM_001160112, b) NM_001077632, c) NM_001110222, NM_001110224, NM_001110223, d) 
NM_001038698, e) NM_001122889, f) NM_183274, g) XM_913832, h) NM_001042451, i) NM_001038609
regional patterning is thought to be achieved by cell-extrinsic, 
contrasting gradients of morphogens and growth factors, includ-
ing Bone Morphogenetic Proteins (BMPs), Sonic Hedgehog 
(Shh), Retinoic acid, Fibroblast Growth Factors (FGFs), etc. 
these chemical gradients establish a positional axis that confers 
region-specific	patterns	of	gene	expression	and	directs	lineage-
specific	differentiation.	This	information	has	been	used	to	com-
pile the list of markers for in vitro differentiation (tab. 2). the 
translation of knowledge from developmental gene expression 
to in vitro gene expression is not without caveats. For instance, 
the gradients formed in vivo are complex and not stable over 
time. For instance, NSC formation in the neural tube structure 
begins rostrally, and zones of NSC formation and patterning are 
moving in a rostro-caudal (from head to tail) way along the neu-
ral tube (Wilson and Maden, 2005). In vivo neurulation is also a 
desynchronised process. Homogenates used for transcriptional 
and neuronal differentiation. the differentiation process is usu-
ally not 100% synchronised, and cellular differentiation stages 
form a continuum. therefore, the wave of NSC gene expression 
may overlap with the antecedent meSC gene expression and 
with the following wave of NSC-derived neuronal/glial gene 
expression.	Consequently,	 it	 is	difficult	 to	strictly	define	NSC	
patterns of gene expression solely within the context of an in 
vitro differentiation system. For this reason, changes in gene ex-
pression are interpreted with reference to those observed during 
neural	specification	and	lineage	progression	in vivo (Rubenstein 
and Puelles, 1994; Rubenstein et al., 1998).
A basic characteristic of the nervous system is the high diver-
sity of different cell types, which is necessary for appropriate 
function.	Neuronal	differentiation	proceeds	in	a	region-specific	
manner, depending on the position of neuroepithelial progeni-
tors along the rostrocaudal or dorsoventral axes (Fig. 2). this 
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Similar processes occur also in in vitro culture, which ex-
plains that e.g. the density of cells has a major impact on the 
end result of the differentiation. Chemicals can act in this phase 
on the cells or their signalling molecules, and the exposure 
may result in a shift of the balance between neuronal subtypes 
(Gaspard et al., 2008) or between glia and neurons (Fritsche et 
al., 2005; Steinhart et al., 2007). Such early events have been 
speculated to have a late impact e.g. on development of neuro-
degenerative disease (landrigan et al., 2005), and it has been 
demonstrated experimentally that e.g. exposure to polychlorin-
profiling	will	 contain	 both	NSCs	 and	 differentiating	 neurons.	
therefore, NSC and their progeny can be hard to disentangle 
at the level of transcription without reference to cellular, spatial 
distinctions	in	gene	expression	profiles	(e.g.	as	determined	by	
high resolution in situ hybridisation). 
Ideally, meSC-derived NSC gene expression should broadly 
recapitulate developmental patterns of gene expression ob-
served	 during	 neuroepithelium	 specification,	 or	within	 prolif-
erative progenitor zones at later stages. Such information has 
also	been	used	here	(amongst	others)	for	filtering	of	suggested	
marker genes (Fig. 2). For our compilation, we used the strong 
expression	 and/or	 significant	 role	 of	 a	 gene	 in	 differentiated	
neurons	 and/or	 glia	 as	 exclusion	 for	 its	 definition	 as	 an	NSC	
marker, even though the gene may be expressed in NSCs. this 
important	filtering	step	is	admittedly	biased,	and	new	informa-
tion will require adaptations.
A different approach would be to look at functional impor-
tance. While some of the most frequently used meSC markers 
also have a functional role in stemness, many of the typical NSC 
and radial glia markers are e.g. cytoskeletal elements (Nestin, 
Gfap, Vimentin) without known function in NSC maintenance. 
Others, with known and important functions, such as the tran-
scription factors Sox2 or Zic1, or signal transduction molecules 
like Jak2, Hes5 and Fgfr3 also have roles in other cells. thus, at 
present, it appears necessary to combine all different approach-
es	to	select	candidate	NSC	genes	and	to	further	filter	those	by	
manual cherry-picking based on literature studies. Such at-
tempts have been made repeatedly, and the table (tab. 2) pre-
sented here is strongly based on the publications of Abranches 
et al., 2009; Maisel et al., 2007; Kelly et al., 2009; Vogel et al., 
2009; Gaspard et al., 2008; liu et al., 2004; Barberi et al., 2003; 
Ghosh et al., 2008.
4.5  Definition of differentiation markers for 
different neuronal stages
After the generation of NSC, neuronal differentiation proceeds. 
the currently accepted model of neural developmental pro-
poses that extracellular signalling molecules act on NSC and 
their progeny and determine what type of neurons or glia they 
will become. this would be accompanied by migration of the 
neuroblasts and by generation of new signalling gradients due 
to factors secreted from neural cells themselves. Cells at a dif-
ferentiation stage after the NSC stage that are not yet mature 
neurons are frequently referred to as neuroblasts. However, the 
definition	of	these	cells	has	some	caveats.	During	organ	devel-
opment, the neuroblast is essentially a post-mitotic neuron that 
is distinguished from a maturing or mature neuron by its spe-
cialisation for migration rather than for functional integration. 
Postnatally, neuroblasts are a distinct population of cells, which 
are capable of proliferation and are neuronally committed. 
therefore, we use the expression NSC in this review to signify 
proliferative cells with self-renewal capacity, the ability to form 
neuronal and glial cells, and a dependence on eGF and bFGF 
for optimal proliferation (meSC depend on lIF). the neuronally 
committed progeny of NSC includes maturing neurons at differ-
ent stages, which we denote as “neuroblasts” when referring to 
early stages and as neurons when referring to late stages.
Fig. 2: Basic concepts of neurodevelopment
Very early during embryonic development (about day 7.5) the 
neural plate forms as an area of early neuroectodermal tissue, 
whereas flanking regions form ectoderm (ED). 
A. Within the next 24 h this plate invaginates and closes to form 
the neural tube, which is the precursor stage of the central nervous 
system. Cells at the lateral margins of the neural tube form the 
neural crest cells (NC) that migrate to various locations and form 
parts of the peripheral nervous system among other cell types. 
B. The neural tube (light gray) is flanked by non-neural tissue (dark 
grey) and extends from the head region towards the prospective 
tail region. At this stage, clear patterns of neurons along 
different axes are established, which lead to different neuronal 
subpopulations in the adult. The major axes are from back  
(dorsal = d) to belly-side (ventral = v) and from head (rostral = r)  
to tail-side (caudal = c). 
C. lateral view of a day 10.5 embryo (E10.5): the caudal end (c) 
represents the spinal cord (SC), the rostral end (r) develops into 
the brain, where forebrain (FB), midbrain (MB) and hindbrain 
(HB) can be distinguished. The dorso-ventral axes (d-v) remains 
present both in the spinal cord (motor neurons in the ventral part) 
and in the brain (e.g. the dorsal forebrain differentiates to cortical 
structures (Ctx). 
D. Embryonic stem cells (ESC) can differentiate to neural stem 
cells (NSC) with characteristics resembling those of proliferating 
cells found in the early development of the nervous system.  
The mESC-derived NSC-like cells, like their in vivo counterparts, 
retain the capacity to acquire region-specific identities and 
differentiate into neurons and/or glia via intermediate lineage-
restricted progenitor cell stages in vitro.
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4.6  Astrocyte markers
A discussion of all markers relevant for the different develop-
mental phases is beyond the scope of this review. As one ex-
ample for the complexity, we chose a relatively simple neural 
population: astrocytes. Although these cells make up more than 
half of the brain mass, they have been relatively neglected as 
potential targets of toxicity or DNt. It is generally assumed that 
astrocytes	 are	 identified	 by	 the	 intermediary	 filament	 protein	
GFAP. However, recent research has shown that antibodies to 
this protein also label radial glia (NSC-related cells) (Seri et al., 
2001; Ganat et al., 2006; Götz and Steindler, 2003; Buffo et al., 
2008), and that about 50% of astrocytes in the brain may not ex-
press	significant	amounts	of	GFAP	(Lovatt	et	al.,	2007;	Cahoy	
et al., 2008). Moreover, knockout of Gfap has no major effects 
on astrocyte development or brain function (Pekny et al., 1995; 
Gomi et al., 1995). thus, a broader panel of astrocyte mark-
ers, as compiled here (tab. 5), is urgently needed, similar to the 
markers for meSC and mNSC presented in tables 1 and 2. 
ated biphenyls (PCBs) in utero can affect the outcome of stroke 
in later life without major effects on brain development (Dzien-
nis et al., 2008). thus, we have to assume that DNt does not 
necessarily affect the number of neurons or other major cell 
types,	but	the	specific	patterning	of	the	nervous	system	and	re-
lationships between neuronal populations. For such endpoints, 
transcriptional	profiling	at	different	phases	of	development	ap-
pears to be a useful approach to detect deviations from the nor-
mal	pattern.	An	example	of	markers	to	define	such	patterning	
is	displayed	in	Table	4.	A	future	refinement	may	be	the	selec-
tion of differentially spliced genes that form highly cell-type or 
development-specific	transcripts.	For	instance	the	well	known	
neuronal	marker	NeuN	affects	neuronal-specific	splicing	(Kim	
et	al.,	2009b),	and	 the	mitochondrial	 fusion-fission-regulating	
gene Drp1	expresses	a	specific	splice	variant	only	in	brain	(Uo	
et al., 2009). New microarray platforms that allow reliable de-
tection of exon splicing may enable detailed analysis of post-
mitotic neuronal differentiation.
Tab. 5: Marker genes for astrocytes
name accession number full name comment reference
ActA2 NM_007392 Alpha-actin-2 also in smooth muscle  [1]
Aldh1L1 NM_027406 Aldehyde dehydrogenase family 1 member L1 also in GFAP-neg AC [2]
AldoC NM_009657 Fructose-bisphosphate aldolase C  [3]
ApoE NM_009696 Apolipoprotein E also synthesised by MG [4]
Aqp4 NM_009700 Aquaporin-4 also RG, endfeet at vessels [5], [6]
Bysl NM_016859 Bystin in reactive AC [7]
Car2 NM_009801 Carbonic anhydrase 2 also in OC 
Cbs NM_178224a) Cystathionine beta-synthase  [3]
Csad NM_144942 Cysteine sulfinic acid decarboxylase taurine biosynthesis 
Gfap NM_001131020b) Glial fibrillary acidic protein labels subset of AC [8], [9]
GjA1 NM_010288 Connexin 43 AC specific in the brain [6], [10]
GjB6 NM_001010937c) Connexin 30  [10]
Glul NM_008131 Glutamine Synthetase also in GFAP-neg AC [11], [12]
Kcnj10 NM_001039484 ATP-sensitive inward rectifier potassium channel 10, Kir4.1 absent in immature AC [3]
MaoB NM_172778 Monoamine oxidase type B mitochondrial  
NFIA NM_010905d) Nuclear factor 1 A-type also in OC, NSC [13]
NFIB NM_001113209e) Nuclear factor 1 B-type also in OC, NSC [13]
NFIX NM_001081982f) Nuclear factor 1 X-type also in OC [13]
Pla2g7 NM_013737 PAF acetylhydrolase useful RNA marker [2]
PygB NM_153781 Glycogen phosphorylase, brain form specific for AC in brain [14]
S100b NM_009115 S100beta also in early AC, NSC [15]
Slc1A2 NM_001077515g) GLT-1, excitatory amino acid transporter 2 early AC, also NSC, RG [16]
Slc1A3 NM_148938 Glast-1, excitatory amino acid transporter 1 mature AC [16]
SparcL1 NM_010097 SC1, SPARC-like protein 1  [17]
Vim NM_011701 Vimentin also RG, NSC, early AC [18], [19]
AC: astrocytes; RG: radial glia; NSC: neural stem cells;  OG: oligodendrocytes; MG: microglia
Additional accession numbers:  
a) NM_144855, b) NM_010277, c) NM_008128, d) NM_001122952, NM_001122953, 
e) NM_008687, NM_001113210, f) NM_010906, NM_001081981, g) NM_011393, NM_001077514
1: Lecain et al., 1991; 2: Cahoy et al., 2008; 3: Hatada et al., 2008; 4: Gee et al., 2005; 5: Nakahama et al., 1999; 6: Fatemi et al., 2008;  
7: Sheng et al., 2004; 8: Rodnight et al., 1997; 9: Ghandour et al.,, 1979; 10: Lovatt et al., 2007; 11: Steffek et al., 2008; 12: Wu et al., 2005; 
13: Wilczynska et al., 2009; 14: Pfeiffer et al., 1992; 15: Burette et al., 1998; 16: Chaudhry et al., 1995; 17: McKinnon et al., 1996;  
18: Dahl et al., 1981; 19: Zamora et al., 1988
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5  Conclusions
the transcription-based markers discussed in this review 
represent an effort to characterise subtle disturbances in the 
waves of gene inductions leading from meSC to differentiated 
neural	cells.	With	more	experience,	and	for	specific	applica-
tions, possibly small subgroups of markers can be selected 
to obtain relevant information. A step further would be the 
use	 of	 genetically-modified	mESC	with	 reporter	 constructs.	
In	 this	 case,	 easily	 quantifiable	 enzymes,	 like	 luciferase	 or	
secreted alkaline phosphatase (Suter et al., 2009; Volbracht 
et	 al.,	 2009),	 driven	 by	 cell-	 and	 stage-specific	 promoters	
would be used as endpoints of gene induction, also in very 
complex cell mixtures. As with all transcription-based assays, 
the endpoints suggested here do not necessarily correlate with 
protein or function, and this issue will require further charac-
terisation	and	validation	(Schrattenholz	and	Soskić,	2008).	In	
the end, the proof of the pudding is in the eating. In extreme 
cases, certain well-established markers cannot be detected 
at all on the RNA-level for technical reasons (e.g. highly re-
petitive	sequences)	or	because	they	are	antigenically	defined.	
these comprise the early astrocyte precursor marker A2B5, 
the meSC marker SSeA-1 or the NSC marker polysialylated-
NCAM	 (PSA-NCAM).	 Such	markers	 are	 linked	 to	 specific	
glycosylations or keratin sulfates, and in extreme cases gly-
cosylation itself (GalNAc-epitopes on multiple proteins) can 
be an excellent marker for meSC (Nash et al., 2007). Such 
antigenic markers are ideally combined with RNA markers 
and, in the future, RNA marker sophistication will increase 
by the inclusion of miRNAs, lincRNAs or other non-coding 
RNAs,	and	of	tissue	specific	splice	variants.	Altogether,	 this	
approach	seems	to	be	powerful	enough	to	define	exactly	the	
differentiation capacity of eSC, also to germ layers other than 
neuroectoderm, and it should therefore be a suitable substitute 
for old-fashioned assays testing teratoma formation in vivo to 
establish pluripotency of a cell population. this review fo-
cussed mainly on meSC differentiation, but the underlying 
principles also apply to heSC. For the human counterparts, 
some excellent compilations of stem cell markers exist (Assou 
et al., 2007; International Stem Cell Initiative, 2007; Bhatta-
charya et al., 2005, 2009), and it needs to be noted in this con-
text that clear species differences may exist (Ginis et al., 2004; 
Sato et al., 2003). For instance, the above mentioned marker 
SSeA-1 does not work for heSC, while those are character-
ised by SSeA-3/4, which do not work for meSC. Genes like 
threonine dehydrogenase (tdh) (Wang et al., 2009), FoxD3 
or the genes coding for the receptor of the meSC growth fac-
tor lIF (which is dispensable for heSC) are regulated in a 
species-specific	manner.	With	 these	well	 known	 differences	
taken into account, meSC still remain a very robust system for 
studying neural development and are possibly able to provide 
human DNt relevant information on compounds more sensi-
tively than the currently used animal models.
Most	notably,	the	underlying	principle	for	the	definition	of	as-
trocyte markers differs from that of stem cell markers. All of the 
stem cell markers are expected to be expressed in all stem cells. 
In contrast to this, not all “astrocyte markers” are expressed in 
all	astrocytes.	They	rather	define	subpopulations	of	astrocytes	
and different developmental stages of such subpopulations. 
Only this comprehensive picture based on multiple markers will 
yield meaningful information on the fate of the diverse group of 
astrocytes	as	a	whole	and	on	effects	of	chemical	and	other	influ-
ences on their development.
4.7  Toxicity pathways
In this review we have focussed on markers useful for the des-
cription of subtle phenotypic effects caused by toxicants – in-
dependent of their mode of action. An interesting additional 
aspect of transcription-based endpoints may be the possibility 
to	identify	cellular	toxicity	pathways	and	fingerprints	involved	
in	the	effect	of	the	chemicals.	Especially	fingerprinting	is	al-
ready established for other organ toxicities, in particular hepa-
totoxicity (Ruepp et al., 2005; Steiner et al., 2004; Blomme 
et al., 2009). these two different approaches may be applied 
independently or be combined. An example may best demon-
strate the underlying principle: For instance, a chemical may be 
identified	as	a	potential	developmental	neurotoxicant	based	on	
shifts in the patterning markers presented in table 5. It may e.g. 
increase dorsal markers and decrease ventral markers relative 
to house keeping genes. On closer (mechanistic) examination, 
one may notice, that in particular sonic hedgehog (Shh) target 
genes were down-regulated upon exposure to the chemical. 
the mechanism of toxicity may thus involve inhibition of Shh 
signalling.	Alternatively,	chemicals	may	be	screened	specifi-
cally for disturbances of key signalling pathways by reporter 
assays or transcriptome analysis coupled with systems biology 
approaches.	One	compound	may	be	identified	to	block	the	Shh	
signalling pathway, and upon subsequent examination of DNt 
effects, it would lead to a dorsalisation of the developing neu-
rons. Cyclopamine is a substance that behaves as described 
above.	Other	 toxicity	 pathways,	which	may	 be	 identified	 in	
a similar manner, involve e.g. retinoic acid synthesis, notch 
processing or Wnt, tGF-beta or Ah-receptor signalling. the 
above examples show the independence of mechanistic and 
phenotypic approaches and the huge potential of using and 
combining both. In the context of eSC-based neurodevelop-
mental test systems, it is important to note that the phenotypic 
approach	necessarily	requires	a	complex	and	difficult	experi-
mental test system (differentiating eSC). In contrast to this, 
the mechanistic approach may also be applied to (and work 
much better in) much simpler systems involving the respec-
tive pathways. Differentiating eSC are in fact, due to their 
complexity, not very suitable as a mechanistic screen system. 
this review has predominantly focussed on the markers that 
may be useful for DNt/teratogenicity screening approaches 
in the nearer future.
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